[1]CurrentPatentAssignee:LIGANDPHARMACEUTICALSINC-WO2009/156737,2009,A1Locationinpatent:Page/Pagecolumn30-31
[1]CurrentPatentAssignee:CORVUSPHARMACEUTICALSINC-WO2018/183965,2018,A1
[1]CurrentPatentAssignee:CORVUSPHARMACEUTICALSINC-WO2018/183965,2018,A1
[1]Patent:WO2018/183965,2018,A1.Locationinpatent:Paragraph0350;0351;0352;0353;0354
Title: Stephen Willingham, et al. Abstract PR04: CPI-444: A potent and selective inhibitor of A2AR induces antitumor responses alone and in combination with anti-PD-L1 in preclinical and clinical studies.Cancer Immunoly Research. September 25-28, 2016.